Pancreatic Cancer Trial, Recruiting NCT06601010 Sponsor: Ruijin Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06601010
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with pancreatic cancer through laboratory testing and whose doctors have determined they need combination immunotherapy based on clinical guidelines
  • People who have signed and dated a consent form agreeing to take part in the trial
  • People who are willing and able to follow all study procedures and take part in the full research process
  • People between 18 and 75 years old
  • People who are in reasonably good general health and are expected to live for more than 6 months

Who may not be able to join:

  • People with serious illnesses that the trial researchers consider too risky for participation, such as severe heart or lung failure, severely reduced bone marrow function, or serious liver or kidney problems
  • People who have a hole in their intestine (intestinal perforation) or a complete blockage of the intestine
  • People who are pregnant, may be pregnant, or are currently breastfeeding
  • People who are unlikely to be able to follow the study rules and requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13524945287

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
24 September 2024
Est. completion
31 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Evaluation the responses to immunotherapy of pancreatic cancer; Standardized uptake value(SUV); Target-to-background ratio(TBR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov